Announced Thu, 13 Aug · 10:53 IST
Promoter Docon sells 9.90% stake in Thyrocare; holding drops to 51.02%
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.8%1-day move
₹643.05
prior close
₹615.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.2-0.3-1.7-2.8-3.6-5.1-9.8-11.8-8.9-10.1-14.8——
Up moveDown movePending
AI summary
Thyrocare promoter Docon Technologies sold 1,57,69,696 equity shares (about 9.90% of paid-up capital) via market trades on August 13, 2026. Promoter holding reduced from 60.92% to 51.02% of total paid-up equity share capital. Docon continues to remain a promoter and holding company of Thyrocare after the sale. Disclosure filed under SEBI LODR Regulation 30.
Likely market impact
Large promoter stake sale may weigh on the stock in the short term. Promoter still holds a majority at 51.02%, so no change of control.